循環腫瘤cfDNA（遊離DNA）市場按腫瘤類型、癌症類型、技術、應用和地區分類

Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

循環腫瘤cfDNA（遊離DNA）市場規模預計在2025年為92.2億美元，預計到2032年將達到390.5億美元，2025年至2032年的年複合成長率（CAGR）為22.9%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	92.2億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年年複合成長率：	22.90%	2032年價值預測	390.5億美元

循環腫瘤DNA (ctDNA) 是指在血液中循環的惡性細胞或腫瘤的DNA。細胞核包含其大部分DNA。隨著腫瘤的擴大，細胞會死亡並被新細胞取代。被破壞的死細胞會將其內容物（包括DNA）排放到血液中。 ctDNA是一小段DNA，通常長度少於200個鹼基。 ctDNA的數量因人而異，並受腫瘤類型、位置以及惡性腫瘤分期的影響。循環腫瘤DNA (ctDNA) 通常包含可用於癌症檢測的基因變異。 ctDNA的其他重要應用包括預後、治療監測和腫瘤體積估計。如果新的癌症檢測方法能夠在治癒率最高的早期、無症狀階段檢測出癌症，其臨床效用將達到最大程度。循環腫瘤DNA分析有助於早期發現癌症，並可用於提供分子標靶治療。

市場動態

主要企業擴大採用產品發布等內部成長策略來擴大產品系列，預計這將在預測期內推動市場成長。例如，下一代分子診斷公司 BillionToOne Inc. 宣佈於 2022 年 7 月推出首款腫瘤液態切片產品 Northstar Select 和 Northstar Response。這些產品目前可供部分學術癌症中心進行研究。 Northstar Select 是全面的泛癌症體細胞突變分析面板。利用 BillionToOne 專有的分子計數技術，即定量計數模板 (QCT)，該面板在識別可操作突變方面實現了顯著的檢測極限。同時，Northstar Response 是一種基於甲基化的組織診斷治療反應監測試驗。

本研究的主要特點

本報告對全球循環腫瘤cfDNA（遊離DNA）市場進行了詳細分析，並提供了預測期2025-2032的市場規模和年複合成長率（CAGR%），假設2024年為基準年。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
它根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，介紹了全球循環腫瘤 cfDNA（無細胞 DNA）市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
這份全球循環腫瘤cfDNA（遊離DNA）分析報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球細胞吸收腫瘤 DNA 市場的各種策略矩陣來更輕鬆地做出決策。

Biocept, Inc.
Illumina, Inc.
Quest Diagnostics Incorporated
KURABO INDUSTRIES LTD
PerkinElmer chemagen Technologie GmbH
Biodesix
Guardant Health
QIAGEN
Sequenom, Inc.
Agilent Technologies, Inc.
Fluxion Biosciences Inc.
Natera, Inc.
Agena Bioscience, Inc.
Paragon Genomics, Inc.
Lucence Health Inc.
Eurofins Genomics
Thermo Fisher Scientific

第 11 章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI5819

Circulating Cell-Free Tumor DNA Market is estimated to be valued at USD 9.22 Bn in 2025 and is expected to reach USD 39.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 9.22 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	22.90%	2032 Value Projection:	USD 39.05 Bn

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:
- Malignant Tumors
- Precancerous Tumors
Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Global Circulating Cell-Free Tumor DNA Market, By Technology:
- PCR
- Massively Parallel Sequencing
- Single Nucleotide Polymorphism
Global Circulating Cell-Free Tumor DNA Market, By Application:
- Cancer Diagnosis
- Targeting Therapeutics
- Prognosis Indication
Global Circulating Cell-Free Tumor DNA Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Biocept, Inc.
- Illumina, Inc.
- Quest Diagnostics Incorporated
- KURABO INDUSTRIES LTD
- PerkinElmer chemagen Technologie GmbH
- Biodesix
- Guardant Health
- QIAGEN
- Sequenom, Inc.
- Agilent Technologies, Inc.
- Fluxion Biosciences Inc.
- Natera, Inc.
- Agena Bioscience, Inc.
- Paragon Genomics, Inc.
- Lucence Health Inc.
- Eurofins Genomics
- Thermo Fisher Scientific

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Tumor Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Malignant Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Precancerous Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
PCR
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Massively Parallel Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Single Nucleotide Polymorphism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Application, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cancer Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Targeting Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Prognosis Indication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

9. Global Circulating Cell-free Tumor DNA Market, By Region, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Biocept, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Quest Diagnostics Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
KURABO INDUSTRIES LTD
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PerkinElmer chemagen Technologie GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biodesix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Guardant Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
QIAGEN
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sequenom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Fluxion Biosciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Natera, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agena Bioscience, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Paragon Genomics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lucence Health Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eurofins Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies